15th Lipid and Atherosclerosis Forum
From Bench to Bedside: Recent advances in Lipoproteins, Cardiometabolic Disorders and Atherosclerosis Translated to a Better Patient Care
Monday, 1st December 2025
(Day 1)
| 11:30 | Lunch and registration | |
| 12:50 | Welcome and introduction | Prof Handrean Soran |
| 13:00 | Session 1: | Chairs: Dr Charlotte Dawson and Dr Nigel Capps |
| 13:10 | Service quality status and unmet clinical needs of HoFH and what Lomitapide added? Data from UK HoFH project. | Dr Hannah Delaney, UK. |
| 13:30 | Experience with Evinacumab: Data from Italy. | Dr. Elena Fornari, Italy |
| 13:50 | Lipid-lowering therapy in women of childbearing age and during pregnancy: Challenges and management. | Dr Kate Shipman, UK. |
| 14:10 | Rare and challenging cases of chylomicronaemia syndrome. | Dr Paul Downie, UK. |
| 14:30 | Panel Discussion | |
| 14:50 | Coffee Break | |
| 15:15 | Session 2: | Chairs: Mrs Jules Payne and Dr Michael France |
| 15:20 | An update on gene editing based therapies in lipidology. | Dr Steve Richards, USA. |
| 15:40 | Development of bi-specific ANGPTL3-DGAT2 siRNA therapies for cardio-metabolic diseases. | Dr Mike Khan, UK. |
| 16:00 | What is new in the management of severe hypertriglyceridaemia? | TBC |
| 16:20 | Cardiometabolic risk in Patients with Adrenal Incidentalomas and Mild Autonomous Cortisol Secretion: A Call for Action. | Dr Alessandro Prete, UK. |
| 16:40 | Panel Discussion | |
| 17:00 | CLOSE | |
| 18:30 | Coach will depart from the hotel for dinner (speakers and chairs) | |
| 22:00 | Transport back to Double Tree by Hilton, Manchester Airport |
Tuesday, 2nd December 2025
(Day 2)
| 08:20 | Coffee/Tea and registration. | |
| 09:00 | Welcome and Introductions | Prof Handrean Soran |
| 09:05 | Session 3: Identifying and managing cardiometabolic risk in different patient groups. | Chairs: Professor Jamal Basheer and Dr Maryam Ferdousi |
| 09:10 | Managing cardiovascular risk in type 1 diabetes. | Dr Jonathan Schofield, UK |
| 09:30 | Emerging relationship between cardio-metabolic health and cancer. | Dr Safwaan Adam, UK |
| 09:50 | Diagnosis and managing metabolic dysfunction-associated steatotic liver disease. | Prof Christopher Byrne, UK |
| 10:15 | Managing Cardiovascular risk in patients with High triglyceride. | Prof Handrean Soran, UK |
| 10:35 | Panel Discussion. | |
| 10:55 | Coffee Break | |
| 11:20 | Session 4: HDL and LDL cholesterol. | Dr Ahai Luvai and Dr Fiona Jenkinson |
| 11:25 | HDL Properties: An update on recent advances and meanings. | TBC |
| 11:45 | An update on CETP inhibitors clinical trials. | Prof John Kastelein, Netherlands. |
| 12:05 | LDL Cholesterol Lowering in 2025: Unmet needs, optimal targets, and options beyond statins and ezetimibe. | Dr Sanjeev Sharma, UK. |
| 12:25 | Hyperlipidaemia and cerebrovascular disease: What the UK guidelines recommend? | Dr Jai Cegla, UK. |
| 12:45 | Panel Discussion | |
| 13:05 | Lunch | |
| 14:00 | Session 5: The Spectrum of adipose disorders: From lipodystrophy to obesity. | Chairs: Dr Andreas Tridimas and Dr Alaa Razik |
| 14:05 | Lipodystrophies: Classification and Management. | Prof Robert Semple, UK. |
| 14:25 | Managing Obesity: New Horizons and Persistent Challenges. | Professor Akheel Syed, UK. |
| 14:45 | Panel Discussion | |
| 15:05 | Coffee Break | |
| 15:30 | Session 6 Managing hyperlipidaemia and weight: From evidence to everyday practice. |
Chairs Dr Prasanna Rao-Balakrishna and TBC |
| 15:35 | Weight management and the microvasculature: benefits, risks, and misconceptions | Dr Shazli Azmi, UK. |
| 15:55 | Managing hyperlipidaemia made easy: Simple, evidence based and NICE TAs compliant flowcharts to support non-specialists. | Dr Aseem Mishra, UK. |
| 16:15 | Panel Discussion | |
| 16:30 | Close | Prof Handrean Soran |
This meeting has been fully organised by the UK Lipid and Atherosclerosis Forum team/Manchester University Hospitals NHS Foundation Trust and endorsed by HEART UK. The sponsors have had no input or influence into the agenda, content, or selection of speakers of this meeting.
Sponsors: Arrowhead, Chiesi, Daiichi-Sankyo, Novartis, Sobi, Verve, Ultragenyx.
